• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

细胞角蛋白19片段21-1(CYFRA21-1)在膀胱癌患者中的临床价值:埃及的经验。

The clinical value of CYFRA21-1 in bladder cancer patients: Egyptian experience.

作者信息

el-Ahmady O, Halim A B, el-Din A G

机构信息

Biochemistry Department, Faculty of Pharmacy, Al-Azhar Univ., Nasr City, Cairo, Egypt.

出版信息

Anticancer Res. 1999 Jul-Aug;19(4A):2603-8.

PMID:10470202
Abstract

There are a wide variety of tumor markers now available that proved to be of value in the management of cancer patients. Of these markers, tissue polypeptide antigen (TPA) and tissue polypeptide specific antigen (TPS) are well known in the field of bladder cancer. TPA was found to be a mixture of cytokeratins 8, 18 and 19 and recent investigations proved that TPS is keratin 18. The aim of the present study was to assess the clinical value of urinary cytokeratin 19 (CYFRA21-1) in the differential diagnosis between bladder cancer and benign urinary tract diseases represented by bilharziasis. Two hundreds and seventy individuals were included in the present study: 186 with bladder cancer representing the different stages and grades, 44 with urinary tract bilharziasis and 40 normal healthy controls. CYFRA21-1 was evaluated in 24-hour urine samples by ELISA using the automatic set supplied by Boehringer Manheim, Manheim, Germany (ES 300). Results of this study revealed significant elevation of CYFRA21-1 in bladder cancer followed by bilharziasis. 82.3% (153/186) of bladder cancer patients and 11.4% (5/44) of bilharzial patients exhibited CYFRA21-1 levels above the upper limit of the control group (3 micrograms/24-hr). CYFRA21-1 was more sensitive in advanced than early stages of bladder cancer and in patients with positive than those with negative lymph nodes, but association of tumor with bilharziasis did not markedly affect its level.

摘要

目前有各种各样的肿瘤标志物,它们在癌症患者的管理中被证明具有价值。在这些标志物中,组织多肽抗原(TPA)和组织多肽特异性抗原(TPS)在膀胱癌领域广为人知。TPA被发现是细胞角蛋白8、18和19的混合物,最近的研究证明TPS是角蛋白18。本研究的目的是评估尿细胞角蛋白19(CYFRA21-1)在膀胱癌与以血吸虫病为代表的良性泌尿系统疾病鉴别诊断中的临床价值。本研究纳入了270名个体:186例患有代表不同分期和分级的膀胱癌,44例患有泌尿系统血吸虫病,40例为正常健康对照。使用德国曼海姆宝灵曼公司提供的自动检测设备(ES 300),通过酶联免疫吸附测定法(ELISA)在24小时尿液样本中评估CYFRA21-1。本研究结果显示,CYFRA2在膀胱癌患者中显著升高,其次是血吸虫病患者。82.3%(153/186)的膀胱癌患者和11.4%(5/44)的血吸虫病患者CYFRA21-1水平高于对照组上限(3微克/24小时)。CYFRA21-1在膀胱癌晚期比早期更敏感,在有阳性淋巴结的患者中比阴性淋巴结患者更敏感,但肿瘤与血吸虫病的关联并未明显影响其水平。

相似文献

1
The clinical value of CYFRA21-1 in bladder cancer patients: Egyptian experience.细胞角蛋白19片段21-1(CYFRA21-1)在膀胱癌患者中的临床价值:埃及的经验。
Anticancer Res. 1999 Jul-Aug;19(4A):2603-8.
2
Combined assay of CYFRA21-1, telomerase and vascular endothelial growth factor in the detection of bladder transitional cell carcinoma.细胞角蛋白19片段21-1、端粒酶及血管内皮生长因子联合检测在膀胱移行细胞癌诊断中的应用
Int J Urol. 2007 Feb;14(2):108-11. doi: 10.1111/j.1442-2042.2007.01670.x.
3
Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.核基质蛋白、纤连蛋白、膀胱癌抗原及晨尿细胞学检查在膀胱肿瘤检测中的比较评估
J Urol. 2002 Aug;168(2):465-9.
4
Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-1, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma.评估尿肿瘤相关胰蛋白酶抑制剂、细胞角蛋白19片段(CYFRA 21-1)及膀胱癌抗原用于检测高级别膀胱癌的情况。
Urology. 2008 Nov;72(5):1159-63. doi: 10.1016/j.urology.2008.04.009. Epub 2008 Jun 2.
5
[Clinical usefulness of a new tumor marker CYFRA21-1 in patients with lung cancer].[新型肿瘤标志物CYFRA21-1在肺癌患者中的临床应用价值]
Zhonghua Jie He He Hu Xi Za Zhi. 1998 Jan;21(1):26-9.
6
Initial evaluation of the diagnostic performance of the new urinary bladder cancer antigen test as a tumor marker for transitional cell carcinoma of the bladder.新型膀胱癌抗原检测作为膀胱移行细胞癌肿瘤标志物的诊断性能初步评估。
J Urol. 1999 Apr;161(4):1110-5.
7
[Clinical value of combined detection with urinary bladder cancer antigen, hyaluronic acid and cytokeratin 20 in diagnosis of bladder cancer].膀胱癌抗原、透明质酸和细胞角蛋白20联合检测在膀胱癌诊断中的临床价值
Ai Zheng. 2008 Sep;27(9):970-3.
8
Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.尿CYFRA 21.1在浅表性膀胱癌随访中并非检测复发的有用标志物。
Eur Urol. 2007 May;51(5):1267-74. doi: 10.1016/j.eururo.2006.12.019. Epub 2006 Dec 18.
9
[Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].[尿BTA-TRAK在浅表性移行细胞膀胱癌随访中的应用]
Arch Esp Urol. 2002 Jan-Feb;55(1):41-9.
10
Analytical and prospective evaluation of urinary cytokeratin 19 fragment in bladder cancer.膀胱癌中尿细胞角蛋白19片段的分析及前瞻性评估
J Urol. 2000 Apr;163(4):1116-9.

引用本文的文献

1
Diagnosis and management of complicated urogenital schistosomiasis: a systematic review of the literature.复杂泌尿生殖系统血吸虫病的诊断与治疗:文献系统评价。
Infection. 2023 Oct;51(5):1185-1221. doi: 10.1007/s15010-023-02060-5. Epub 2023 Jul 19.
2
Diagnostic accuracy of cytokeratin-19 fragment (CYFRA 21-1) for bladder cancer: a systematic review and meta-analysis.细胞角蛋白19片段(CYFRA 21-1)对膀胱癌的诊断准确性:一项系统评价和荟萃分析。
Tumour Biol. 2015 May;36(5):3137-45. doi: 10.1007/s13277-015-3352-z. Epub 2015 Apr 9.
3
Bladder cancer 2000: molecular markers for the diagnosis of transitional cell carcinoma.
2000年膀胱癌:诊断移行细胞癌的分子标志物
Rev Urol. 2001 Spring;3(2):85-93.